Related references
Note: Only part of the references are listed.Recent research and development of DYRK1A inhibitors
Liyun Zhao et al.
CHINESE CHEMICAL LETTERS (2022)
2022 Alzheimer's disease facts and figures
Joseph Gaugler et al.
ALZHEIMERS & DEMENTIA (2022)
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
Mattias F. Lindberg et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity
Martin Schroeder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential
Paula Martin Moyano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Alzheimer's Disease, Inflammation, and the Role of Antioxidants
Benjamin Sinyor et al.
JOURNAL OF ALZHEIMERS DISEASE REPORTS (2020)
Chemical Delivery System of MIBG to the Central Nervous System: Synthesis, 11C-Radiosynthesis, and in Vivo Evaluation
Fabienne Gourand et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
The neuropathological diagnosis of Alzheimer's disease
Michael A. DeTure et al.
MOLECULAR NEURODEGENERATION (2019)
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
Dnyandev B. Jarhad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Oxidant/Antioxidant Imbalance in Alzheimer's Disease: Therapeutic and Diagnostic Prospects
Joanna Wojsiat et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective
Ankita Pathak et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature
Thu Lan Nguyen et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a Bio-Oxidizable Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation
Ludovic Peauger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
Antoine Daina et al.
SCIENTIFIC REPORTS (2017)
Delivering FLT to the Central Nervous System by Means of a Promising Targeting System: Synthesis, [11C]Radiosynthesis, and in Vivo Evaluation
Fabienne Gourand et al.
ACS CHEMICAL NEUROSCIENCE (2017)
Amyloid beta: structure, biology and structure-based therapeutic development
Guo-fang Chen et al.
ACTA PHARMACOLOGICA SINICA (2017)
A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules
Antoine Daina et al.
CHEMMEDCHEM (2016)
DYRK1A inhibition as potential treatment for Alzheimer's disease
Silvia Stotani et al.
FUTURE MEDICINAL CHEMISTRY (2016)
1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative Stress
Astrida Velena et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2016)
The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review
Shanmugam Manoharan et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2016)
Human CDC2-Like Kinase 1 (CLK1): A Novel Target for Alzheimer's Disease
Princi Jain et al.
CURRENT DRUG TARGETS (2014)
Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B
Tania Tahtouh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Amyloid Precursor Protein Processing and Alzheimer's Disease
Richard J. O'Brien et al.
ANNUAL REVIEW OF NEUROSCIENCE, VOL 34 (2011)
Activation, regulation, and inhibition of DYRK1A
Walter Becker et al.
FEBS JOURNAL (2011)
The role of DYRK1A in neurodegenerative diseases
Jerzy Wegiel et al.
FEBS JOURNAL (2011)
High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation
David O. Azorsa et al.
BMC GENOMICS (2010)
Through the Gatekeeper Door: Exploiting the Active Kinase Conformation
Fabio Zuccotto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease
Young Shin Ryu et al.
JOURNAL OF NEUROCHEMISTRY (2010)
A One-Step Synthesis of 2,4-Unsubstituted Quinoline-3-carboxylic Acid Esters from o-Nitrobenzaldehydes
Hariharan Venkatesan et al.
JOURNAL OF ORGANIC CHEMISTRY (2010)
Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
Yasushi Ogawa et al.
NATURE COMMUNICATIONS (2010)
Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation
Nora Goeckler et al.
FEBS JOURNAL (2009)
Oxidative stress in Alzheimer disease
Alejandro Gella et al.
CELL ADHESION & MIGRATION (2009)
Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease
Soo-Ryoon Ryoo et al.
JOURNAL OF NEUROCHEMISTRY (2008)
DYRK1A-mediated hyperphosphorylation of Tau - A functional link between Down syndrome and Alzheimer disease
Soo-Ryoon Ryoo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism
V Vingtdeux et al.
NEUROBIOLOGY OF DISEASE (2005)
Manipulation of alternative splicing by a newly developed inhibitor of Clks
M Muraki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
APP processing is regulated by cytoplasmic phosphorylation
MS Lee et al.
JOURNAL OF CELL BIOLOGY (2003)
The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bε at Ser539 and the microtubule-associated protein tau at Thr212:: potential role for DYRK as a glycogen synthase kinase 3-priming kinase
YL Woods et al.
BIOCHEMICAL JOURNAL (2001)
Share Paper
